A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Verastem, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Revolution Medicines, Inc.
National Cancer Institute (NCI)
University of Chicago
Revolution Medicines, Inc.
Erasca, Inc.